MedTrace Logo

Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE)

NCT02154854 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2014-06-03

No results posted yet for this study

Summary

The purpose of this study is to compare parallel-group effects between 4 months and 12 months post-transplantation 2 values of target residual concentrations of Advagraf on vascular parameters in de novo renal transplant patients.

Conditions

  • De Novo Transplant Disease

Interventions

DRUG

Tacrolimus targeted half-dose

DRUG

Tacrolimus targeted plain dose

Sponsors & Collaborators

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Robinson JOANNIDES · University Hospital, Rouen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02154854 on ClinicalTrials.gov